The World Health Organization has delivered more than a million doses of antibiotics to Madagascar amid a raging epidemic of plague in which at least 33 people have died and 230 others have been infected, the BBC reported.
The first confirmed death from the epidemic began on August 28th in the town of Moramanga,.“Plague is curable if detected in time. Plague first arrived in Madagascar from Indian steamboats in 1898 before spreading through other harbors and then into the mainland along railroad construction lines.
New Jersey-based Hackensack Meridian Health has teamed up with the New Jersey Innovation Institute (NJIT) to open a health incubator with a design similar to the reality show ”Shark Tank,” in which companies pitch healthcare innovation ideas to a panel of experts. The incubator, Agile Strategies Lab, is the first of its kind for healthcare advances in New Jersey, according to officials. The lab, located on the New Jersey Institute of Technology (NJIT) campus in Newark, is designed to help create and launch the next wave of problem-solving in healthcare through better devices, improved technology and more efficient services to provide a higher quality of care, lower costs, and an enhanced patient experience, officials said in an announcement.
Hackensack Meridian Health has committed $25 million, a new revenue stream to help companies develop trailblazing products and services. This seed money will help launch ideas to the point where they can become viable and receive financing through venture capitalists. And the organization’s vast network—13 hospitals in seven counties, and more than 100 outpatient centers and 6,000 physicians—will look to serve as a vehicle to test some of the innovations once they are advanced enough as determined by a panel of experts from multiple disciplines.
Penn State professor Ibrahim Ozbolat and his team has engineered a solution to worn out knees. They’re producing cartilage patches to repair defects. Since there are no blood vessels in cartilage tissue, so the researchers said it’s a good type of tissue for bio-printing. In the future, Ozbolat says, stem cells would be removed from a patient and cultured in a lab. The cartilage is printed and then transplanted back into a patient. This will allow scientists to print new and compatible human parts someday.
Dr Jeffrey Lieberman from Columbia University says” the new technologic innovation that is emerging and which does seem likely to impact psychiatry and mental health care in a time that is commensurate with the other specialties of medicine, is the technology that informs how we use Internet-based smartphone mobile app devices. The rudimentary ways in which this has already begun to permeate medicine and mental health care include electronic health records and telemedicine, which is ideally suited to psychiatry in terms of being able to provide consultation at a distance.“The initial idea is to have smartphone-based applications that can perform several functions. One is a monitoring function: having apps that can passively monitor the activities or biologic signals of an individual—whether it is movement, heart rate, respiratory rate, or level of activity—and have an ongoing record that can be catalogued, observed, and interpreted by clinicians. A second function is as a means of communication. Doctors already have begun to employ FaceTime, Skype, and texting to maintain contact with patients remotely in a variety of situations. Another area would be to develop apps that could provide some kind of actual therapeutic assistance, including cognitive-behavioral therapy, motivational interviewing, and supportive types of techniques or protocols when needed. All of these have great potential and can expand the reach of healthcare providers, psychiatrists, and mental health care clinicians, and provide help to a larger proportion of people when they need it.”
In a technique called spindle nuclear transfer, the nucleus of a donor egg is removed and the DNA of another woman’s egg is injected.
The FDA is taking a hard stance on a controversial fertility technique that involves genetically modifying embryos.
The New York-based doctor who helped a couple have a child using DNA from three people has been told by the U.S. Food and Drug Administration to stop the clinical trials meant to test the technique.
Last year, John Zhang, the founder of New Hope Fertility Center, pioneered a new type of in-vitro fertilization that involves transferring DNA from the mother’s egg into a hollowed-out egg donated by a younger woman. But the work violates federal legislation that forbids implanting genetically modified embryos, so after fertilizing the egg with the father’s sperm, Zhang went to Mexico, where he inserted the embryo into the mother’s womb. A healthy baby boy was born in April 2016.
FDA sends Zhang a letter
Zhang then requested a meeting with the agency to ask permission to carry out a clinical trial using the technique in the U.S. The agency subsequently denied the meeting. Zhang has since been marketing his fertility procedure to women with certain genetic diseases and older women having trouble conceiving through a new company called Darwin Life. Modifying embryos in a lab is not illegal under U.S. law as long as federal funds are not used to carry out the work. But implanting one in a woman’s womb so that a baby can develop is prohibited.
23andMe first debuted direct-to-consumer tests meant to predict disease in 2013, but the U.S. Food and Drug Administration quickly clamped down on that and told the company to stop marketing the tests, saying they could be inaccurate and confusing to consumers.
However, the company was vindicated earlier this year when the FDA revised that decision, declaring 23andMe could sell tests that estimate customers’ risk of certain disease, as long as they don’t purport to diagnose any disease.
Early this year, Illumina, the manufacturer of most of the world’s DNA sequencers, unveiled its newest, most efficient machine, NovaSeq, which can sequence as many as 48 entire human genomes in two and a half days, according to the company. Illumina claims the ultra-fast machine will usher in the $100 genome and will open the door for researchers to cheaply sequence DNA in search of rare genetic variants that cause disease.
Sophia Genetics is taking a big-data approach to DNA. The Swiss company is using AI algorithms to continuously learn from thousands of patients’ genomic data. Partnering hospitals take patient samples and run them through a DNA sequencer. The Sophia system sifts through that genetic information to identify mutations in a patient’s genome. The technology is said to quickly and more accurately diagnose conditions like cancer, metabolic disorders, and heart disease.